Loading clinical trials...
Loading clinical trials...
An Open-label, Randomised, Single Dose, Three-way Crossover, Parallel Groups Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 to Respective Reference Dosages in Healthy Adult Male and Female Subjects Under Fasting Conditions
Conditions
Interventions
Reference Treatment: 5 mg amlodipine + 50 mg losartan
Reference Treatment:5 mg amlodipine + 100 mg losartan
+2 more
Locations
1
South Africa
GSK Investigational Site
Bloemfontein, South Africa
Start Date
May 23, 2013
Primary Completion Date
July 25, 2013
Completion Date
July 25, 2013
Last Updated
June 12, 2017
NCT02417740
NCT07480265
NCT07073820
NCT06876233
NCT06062394
NCT06899815
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions